Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related